Sanofi Q2 Earnings Beat Driven by Dupixent Sales Surge Near 30% to Record High

Intelligent Finance APP learned that Sanofi (SNY.US), a pharmaceutical giant headquartered in France, announced an increase in its annual profit forecast for this year in its Q2 earnings report. The company's total sales and profits for the second quarter exceeded analysts' consensus expectations, mainly due to the strong performance of its long-term best-selling products.Atopic DermatitisThe demand for Dupixent, a treatment for asthma symptoms, is very strong.

This Paris-based pharmaceutical giant said on Thursday that, at constant exchange rates, earnings per share excluding certain special items may remain "stable trend" this year. By contrast, the company's previous forecast phrasing was "earnings per share excluding certain items may decline by a low single-digit percentage."

In terms of Q2 performance, driven by Dupixent's sales growth of nearly 30% year-over-year, which surged to a record high of 3.3 billion euros in quarterly sales, Sanofi's adjusted earnings per share for the second quarter reached 1.73 euros (approximately 1.88 US dollars), surpassing analysts' consensus expectations.Driven by the strong demand for Dupixent,Sanofi's total sales in the second quarter reached $10.745 billion, increasing by over 10% year-on-year, exceeding analysts' general expectations by more than 300 million euros.

Dupixent (dupilumab), a monoclonal antibody drug, is used to treat various chronic inflammatory diseases. As a biologic, it alleviates disease symptoms by inhibiting specific components of the immune system and reducing inflammatory responses. Due to its significant breakthroughs in efficacy, safety, and the treatment of chronic inflammatory conditions—especially its notable effectiveness and high safety profile—Dupixent has become a globally popular best-selling drug. By targeting specific immune pathways, it provides crucial relief for patients with atopic dermatitis, asthma, and CRSwNP, making it a valuable tool in treating these conditions.

Sanofi CEO Paul Hudson has already prepared investors for a slowdown in profit growth this year as Sanofi intensifies its innovative drug development initiatives, aiming to create more long-term blockbuster products like Dupixent.

The company is currently following a competitive strategy, similar to rivals including Novartis AG, focusing on cutting-edge drug therapies while divesting some older drugs with expired patents as well as its consumer health division. Sanofi's management’s latest approach involves sacrificing a small portion of current earnings in exchange for faster growth before 2030.

Sanofi CFO Francois-Xavier Roger mentioned during a conference call with reporters that Sanofi expects to make a final decision in the coming months regarding how to spin off its consumer healthcare business unit, internally referred to as Opella. The company is still considering all potential options, including a possible sale or pushing for an independent listing of the unit after the spin-off, with the divestment expected to be completed as early as the fourth quarter.

Investors are looking for early signs that Sanofi can deliver on its promise to produce innovative drugs faster than it has in the past. The company plans to release data from up to 12 late-stage clinical trials before the end of 2025. Currently, many investors are focused on the clinical trial results of Sanofi's experimental treatment for relapsing-remitting multiple sclerosis, tolebrutinib.

Analysts John Murphy and Mila Bankovskaia from Bloomberg Intelligence noted in a report that this is one of the encouraging signs of positive progress in Sanofi's drug development, which could be more important to investors than the company’s improved financial performance.

Sanofi CFO Roger Said in a Teleconference with Reporters that Sanofi Hopes Dupixent Will Receive Formal Approval from U.S. Regulators in September for the Treatment of Chronic Pulmonary Diseases, and Is Prepared to Immediately Begin Offering the Drug to Patients with This Condition. Earlier This Month, European Regulators Approved Dupixent for the Treatment of Chronic Obstructive Pulmonary Disease.

Currently, Sanofi still expects Dupixent's sales this year to reach approximately €13 billion, compared to the drug’s Q2 sales of about €3.3 billion.

Since the beginning of this year, Sanofi has been exploring various options for divesting its consumer healthcare business unit, including a direct sale to private equity firms and pushing for the unit's listing on the secondary market. This division primarily sells over-the-counter products, including Phytoxil cough syrup and Icy Hot pain relief gel.

Media reported earlier this month that private equity firms Advent International and PAI Partners both submitted first-round acquisition offers for Sanofi's business unit, with some proposals valuing the unit as high as 15 billion euros.